Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2005 2
2007 1
2012 2
2013 1
2014 1
2015 2
2016 4
2018 1
2019 1
2020 2
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Results by year
Filters applied: . Clear all
Page 1
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP; Secukinumab in Crohn's Disease Study Group. Hueber W, et al. Among authors: berger c. Gut. 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668. Epub 2012 May 17. Gut. 2012. PMID: 22595313 Free PMC article. Clinical Trial.
Metabolic effects of genetic variation in the human REPIN1 gene.
Krüger J, Berger C, Weidle K, Schleinitz D, Tönjes A, Stumvoll M, Blüher M, Kovacs P, Klöting N. Krüger J, et al. Among authors: berger c. Int J Obes (Lond). 2019 Apr;43(4):821-831. doi: 10.1038/s41366-018-0123-0. Epub 2018 Jun 18. Int J Obes (Lond). 2019. PMID: 29915365
22 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page